|Mr. Edward H. Myles||CFO & Head of Bus. Operations||55k||N/A||1972|
|Dr. Alan J. Buckler||Chief Scientific Officer||542.61k||N/A||1960|
|Dr. Yung H. Chyung M.D.||Chief Medical Officer||564.11k||N/A||1976|
|Mr. Stuart Anthony Kingsley M.B.A., MBA||Pres, CEO & Director||N/A||N/A||1964|
|Ms. Catherine Hu||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, a novel inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corporation’s ISS Governance QualityScore as of December 8, 2019 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 8.